Most Recent
Two founders of the Kaden Boriss international network of law firms have had a copyright case over the company's name and logo thrown out, after a heated spat between partners led to the break-off of the group's Sydney office.
Australian online retailer Catchoftheday.com.au has lost its challenge to a trade mark proposed by a riva online store, with IP Australia citing a lack of evidence for the retailer's claims and a "total impression of dissimilarity" between the marks.
Energy drink giant Monster Energy has dropped its challenge to a ruling allowing alcoholic spirits wholesaler Fernbrew to trade mark the term 'Real Beast' for alcoholic beverages.
Motorola Solutions wants to amend its pleadings in an ongoing patent case against Shenzen-based Hytera Communications to add copyright claims relating to the source code for the radio devices at the centre of the dispute.
The Copyright Agency has brought proceedings against the peak body representing Australia's universities over copyright costs, after negotiations over a new licencing agreement broke down.
Cable TV giant Foxtel has succeeded in a second challenge to a digital download patent by a subsidiary of global tech giant Cognizant, but IP Australia has given the patent owner yet another go at fixing it.
Network 10 told a court Thursday it would "fiercely defend" a trade mark case brought by Fairfax Media over 10's recent rebrand and its newly approved trade mark, 10 Boss.
Keyboard specialist PKT Technologies has returned for an encore in a six-year long trade mark dispute, appealing a $384,000 judgment against it for violating a trade mark licence agreement with engineer Peter Vogel, inventor of the groundbreaking synthesiser behind some of 80s pop music's most iconic sounds.
A court has delivered a loss for Germany-based B. Braun Melsungen, dismissing its allegations that US-based device manufacturer Becton Dickinson infringed three of its intravenous catheter patents and ruling the patents invalid.
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.